Core Insights - CorMedix Inc. (NASDAQ:CRMD) is recognized as a fast-growing small-cap stock, with analysts recommending it as a buy following a strong earnings report for fiscal Q3 2025 [1][2] - The company reported a significant revenue increase of 810.21% year-over-year, reaching $104.28 million, which exceeded estimates by $18.25 million [2] - Earnings per share (EPS) for the quarter was $1.26, surpassing consensus estimates by $0.63 [2] Financial Performance - The revenue growth was primarily driven by higher utilization of DefenCath among outpatient dialysis customers, contributing $88.8 million to net revenue [2] - CorMedix raised its full-year pro forma net revenue guidance to a range of $390 to $410 million and fourth-quarter guidance to $115 to $135 million [3] Strategic Developments - The recent acquisition of Melinta has diversified CorMedix's business and contributed to its robust financial results [4] - The company has a promising pipeline with significant growth catalysts, including anticipated results from the Rezzayo study and TPN Phase 3 data for DefenCath [4] Company Overview - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products aimed at preventing and treating life-threatening infectious and inflammatory diseases [5]

​Delcath Systems, Inc. (NASDAQ:DCTH) is one of the Fast-Growing Small Cap Stocks to Buy According to Analysts. On November 5, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Delcath Systems, Inc. (NASDAQ:DCTH), but lowered the price target from $31 to $30. ​Earlier on November 4, Delcath Systems, Inc. (NASDAQ:DCTH) released results for its fiscal Q3 2025. The company posted a revenue of $20.6 million, up from $11.2 million last year. Moreover, the EPS came in at $0.02, ahead of the ...

Core Viewpoint - Carvana Co. (NYSE:CVNA) is recognized as a top aggressive growth stock, with a Buy rating and a price target of $500 following its strong Q3 2025 results [1][3]. Financial Performance - In Q3 2025, Carvana sold nearly 156,000 retail units, marking a 44% increase year-over-year. Revenue grew by 55% to reach $5.65 billion, both representing all-time quarterly records [2]. - The revenue growth outpaced the increase in retail units sold, primarily due to higher average selling prices [2]. Market Position and Strategy - Needham views Carvana as a leading large-cap growth opportunity, highlighting its clear long-term growth path despite cautious near-term unit guidance [3]. - The company consistently executes its plans and provides long-term guidance, showcasing a strong business model and a competitive edge over rivals with more volatile performances [4]. - Carvana operates a platform for buying and selling used cars, offering online browsing, research, purchasing, financing, trade-ins, and delivery services [4].

Core Viewpoint - EQT Corporation is recognized as one of the best aggressive growth stocks to buy, with Scotiabank maintaining a Sector Perform rating and a price target of $70 following strong Q3 2025 results [1][2]. Financial Performance - In Q3 2025, EQT Corporation reported significant achievements in production, capital expenditure, and free cash flow, attributing this success to operational efficiencies [2]. - Capital expenditures for Q3 2025 were 10% lower than the midpoint of the company's guidance, resulting from ongoing efficiency gains and midstream cost optimization [3]. Operational Highlights - The company set multiple records during the quarter, including the highest pumping hours in a month, the fastest quarterly completion speed, and the most lateral footage drilled and completed in a 24-hour period [2]. - EQT Corporation had a strong and oversubscribed open season for its MVP boost expansion project, leading to a 20% increase in the project's size [3]. Strategic Initiatives - Potential catalysts for EQT Corporation include continued synergy capture from Equitrans, a target to reduce total debt to a maximum of $5 billion, ongoing optimization of the gathering system, and direct supply agreements [4]. - EQT Corporation operates as a vertically integrated natural gas company, focusing on production and midstream operations primarily in the Appalachian Basin [4].

Core Viewpoint - Eli Lilly and Company (NYSE: LLY) is recognized as one of the best aggressive growth stocks, with a Buy rating and a price target of $960 following a government agreement to expand access to obesity medications [1][5]. Group 1: Government Agreement and Pricing - Starting April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound (tirzepatide) and orforglipron, contingent on FDA approval [2]. - The lowest dose of Zepbound will be priced at $299, with higher doses reaching up to $449, which is $50 lower than current prices [3]. - Orforglipron will start at $149 for the lowest dose, with additional doses priced up to $399 [3]. Group 2: Additional Products and Pricing Strategy - Eli Lilly will also offer Emgality (galcanezumab-gnlm), Trulicity (dulaglutide), and Mounjaro (tirzepatide) to self-pay patients at prices 50-60% lower than current list prices [4]. - The pricing deal is expected to accelerate price reductions for these medications, although the long-term impact may be modest due to potential increases in sales and patient adherence [5]. Group 3: Market Position and Future Outlook - Medicare coverage for Zepbound is viewed as a positive development for Eli Lilly, indicating potential growth in patient access and sales [5].

Core Insights - Taiwan Semiconductor Manufacturing Company Limited (TSM) is recognized as one of the best aggressive growth stocks to buy currently [1] - The company's Board of Directors approved a budget of approximately $14.98 billion to support long-term capacity plans based on market demand forecasts and technology development [1][2] Financial Performance - TSM reported total revenue of around TWD 367.47 billion for October 2025, marking an 11% increase from September 2025 and a 16.9% year-over-year growth [4] - For the period from January to October 2025, TSM's revenue reached TWD 3,130.44 billion, reflecting a 33.8% increase compared to the same period in 2024 [4] Investment and Development Plans - The approved capital will be allocated for fab construction, installation of fab facility systems, expansion of advanced technology and packaging capabilities, and funding research and development in 2026 [2]

Core Insights - CRISPR Therapeutics AG is recognized as a leading gene-editing stock, with RBC Capital raising its price target from $42 to $50 while maintaining a Sector Perform rating [1][2] - CASGEVY, CRISPR's primary product, underperformed in Q3 2025, generating $17 million in revenue against a consensus estimate of $41 million, with infusions dropping from 16 in Q2 to 10 in Q3 [2] - Despite the underperformance, Vertex Pharmaceuticals, CRISPR's partner, anticipates over $100 million in total CASGEVY revenue for 2025, suggesting expected Q4 sales of more than $39 million [2] - Citizens maintained a Market Outperform rating with an $86 price target for CRISPR, highlighting promising Phase 1 data for CTX310, which targets ANGPTL3 to combat heart disease related to cholesterol disorders [3] - Phase 1 data for CTX310 indicated significant reductions in circulating ANGPTL3, reinforcing the potential of the in-vivo program [3] - CRISPR Therapeutics specializes in gene-based medicines utilizing CRISPR/Cas9 technology, with key products including CASGEVY and a pipeline featuring CTX310 and CTX112 [4]

Townsquare Media, Inc. (NYSE:TSQ) is included among the 15 Stocks with Highest Dividend to Invest in. Noble Capital Cuts Townsquare Media (TSQ) Price Target After Soft Q3 Results Photo by nathan dumlao on Unsplash On November 11, Noble Capital cut its price ta‌rget o​n Townsquare Media, Inc. (NYSE:TSQ) to $1​5 from $21 while mainta‌ining‍ an Outperform rating. The firm adjusted i‍ts​ out‍look after the c‍ompa⁠ny​’s Q3 res⁠ults a​nd it‌s updated guidance for Q4, w‍hich led to l‍ower expect⁠ations for 202 ...

New Mountain Finance Corporation (NASDAQ:NMFC)⁠ is included among the 15 Stocks with Highest Dividend to Invest in. B. Riley Maintains Neutral Rating on NMFC, Lowers Price Target to $10 Photo by Vitaly Taranov on Unsplash On Nov‌ember 5, B.⁠ Ri‍le‍y l⁠owered it‌s price target on New Mountain Finance Corporation (NASDAQ:NMFC)⁠ t⁠o $10 from $11 and maintained a Neutral rating on the stock f‌o‍llow‍ing t‌he Q3 results, as reported by The Fly. The analyst noted that the company’s raw earnings fell short of ...

Core Insights - Flowers Foods, Inc. (NYSE:FLO) is recognized as one of the 15 Best 52-Week Low Dividend Stocks to Invest in [1] - Truist has reduced its price target for Flowers Foods from $15 to $10 while maintaining a Hold rating, citing mixed Q3 results and narrowed guidance [2] - The company announced a quarterly dividend of $0.2475 per share, marking its 93rd consecutive quarterly dividend and 23 years of dividend increases [3] Company Overview - Flowers Foods operates as one of the largest producers of packaged baked goods in the US, offering a variety of products including fresh breads, buns, rolls, snack cakes, and specialty items [4] - The company is focusing on transforming its portfolio, investing in digital systems, and expanding into high-growth and health-oriented categories [4] Strategic Initiatives - Acquisitions, such as the recent Simple Mills deal, are central to Flowers Foods' strategy to appeal to health-conscious and value-driven consumers [5] - The company's success is linked to brand strength, effective pricing, product mix, disciplined cost control, and adaptability to changing consumer preferences and competitive pressures [5]